Consensus recommendations from the American Acne & Rosacea Society on the management of rosacea, Part 1: A status report on the disease state, general measures, and adjunctive skin care

Cutis

Volumn 92, Issue 5, 2013, Pages 234-240

  Del Rosso, James Q ^a,b   Thiboutot, Diane ^c   Gallo, Richard ^d   Webster, Guy ^e   Tanghetti, Emil ^f   Eichenfield, Larry ^g,h   Stein Gold, Linda ⁱ   Berson, Diane ^j   Zaenglein, Andrea ^c  

^a TOURO UNIVERSITY NEVADA   (United States)

^b Las Vegas Skin and Cancer Clinics   (United States)

^c PENN STATE MILTON S HERSHEY MEDICAL CENTER   (United States)

^d UNIVERSITY OF CALIFORNIA   (United States)

^e THOMAS JEFFERSON UNIVERSITY   (United States)

^f Center for Dermatology and Laser Surgery   (United States)

^g RADY CHILDREN'S HOSPITAL   (United States)

^h UNIVERSITY OF CALIFORNIA   (United States)

ⁱ HENRY FORD HOSPITAL   (United States)

^j NEW YORK PRESBYTERIAN HOSPITAL   (United States)

more..

Author keywords

[No Author keywords available]

Indexed keywords

SUNSCREEN;

ARTICLE; CLASSIFICATION; CONSENSUS; FEMALE; HUMAN; MALE; PRACTICE GUIDELINE; ROSACEA; SKIN CARE; SKIN DISEASE;

CONSENSUS; FACIAL DERMATOSES; FEMALE; HUMANS; MALE; ROSACEA; SKIN CARE; SUNSCREENING AGENTS;

EID: 84888421942     PISSN: 00114162     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (39)

1. Del Rosso JQ, Baldwin H, Webster G; American Acne & Rosacea Society. American Acne & Rosacea Society rosacea medical management guidelines. J Drugs Dermatol. 2008;7:531-533.
2. Del Rosso JQ, Gallo RL, Tanghetti E, et al. An evaluation of potential correlations between pathophysiologic mechanisms, clinical manifestations, and management of rosacea. Cutis. 2013;91(suppl 3):1-8.
3. Wilkin J, Dahl M, Detmar M, et al. Standard classification system of rosacea: report of the National Rosacea Society Expert Committee on the Classification and Staging of Rosacea. J Am Acad Dermatol. 2002;46:584-587.
4. Plewig G, Kligman AM. Rosacea. In: Plewig G, Kligman AM, eds. Acne and Rosacea. 3rd ed. Berlin, Germany: Springer-Verlag; 2000:456-465.
5. Crawford GH, Pelle MT, James WD. Rosacea: I. etiology, pathogenesis, and subtype classification. J Am Acad Dermatol. 2004;51:327-341; quiz 342-344.
6. Odom R, Dahl M, Dover J, et al. Standard management options for rosacea, part 1: overview and broad spectrum of care. Cutis. 2009;84:43-47.
7. Del Rosso JQ. Advances in understanding and managing rosacea: part 1: connecting the dots between pathophysiological mechanisms and common clinical features of rosacea with emphasis on vascular changes and facial erythema. J Clin Aesthet Dermatol. 2012;5:16-25.
8. Del Rosso JQ. Advances in understanding and managing rosacea: part 2: the central role, evaluation, and management of diffuse and persistent facial erythema of rosacea. J Clin Aesthet Dermatol. 2012;5:26-36.
9. Larios G, Alevizos A, Perimeni D, et al. Rosacea-like demodicidosis. Lancet Infect Dis. 2008;8:804.
10. Wilkin J, Dahl M, Detmar M, et al; National Rosacea Society Expert Committee. Standard grading system for rosacea: report of the National Rosacea Society Expert Committee on the classification and staging of rosacea. J Am Acad Dermatol. 2004;50:907-912.
11. Scharschmidt TC, Yost JM, Truong SV, et al. Neurogenic rosacea: a distinct clinical subtype requiring a modified approach to treatment. Arch Dermatol. 2011;147:123-126.
12. Bae YI, Yun SJ, Lee JB, et al. Clinical evaluation of 168 Korean patients with rosacea: the sun exposure correlates with the erythematotelangiectatic subtype [published online ahead of print August 31, 2009]. Ann Dermatol. 2009;21:243-249.
13. Steinhoff M, Buddenkotte J, Aubert J, et al. Clinical, cellular, and molecular aspects in the pathophysiology of rosacea. J Invest Dermatol Symp Proc. 2011;15:2-11.
14. McAleer MA, Lacey N, Powell FC. The pathophysiology of rosacea. G Ital Dermatol Venereol. 2009;144:663-671.
15. Rosina P, Zamperetti M, Giovannini A, et al. Video-capillaroscopic alterations in erythematotelangiectatic rosacea [published online ahead of print November 11, 2005]. J Am Acad Dermatol. 2006;54:100-104.
16. Yamasaki K, Gallo RL. The molecular pathology of rosacea [published online ahead of print May 29, 2009]. J Dermatol Sci. 2009;55:77-81.
17. Fleischer AB Jr. Inflammation in rosacea and acne: implications for patient care. J Drugs Dermatol. 2011;10:614-620.
18. Yamasaki K, Gallo RL. Rosacea as a disease of cathelicidins and skin innate immunity. J Invest Dermatol Symp Proc. 2011;15:12-15.
19. Quarterman MJ, Johnson DW, Abele DC, et al. Ocular rosacea. signs, symptoms, and tear studies before and after treatment with doxycycline. Arch Dermatol. 1997;133:49-54.
20. Ghanem VC, Mehra N, Wong S, et al. The prevalence of ocular signs in acne rosacea: comparing patients from ophthalmology and dermatology clinics. Cornea. 2003;22:230-233.
21. Mannis MJ, Schaller M, Webster G. Ocular rosacea: common and commonly missed. J Am Acad Dermatol. In press.
22. Dirschka T, Tronnier H, Fölster-Holst R. Epithelial barrier function and atopic diathesis in rosacea and perioral dermatitis. Br J Dermatol. 2004;150:1136-1141.
23. Elias PM. The skin barrier as an innate immune element. Semin Immunopathol. 2007;29:3-14.
24. Del Rosso JQ, Levin J. The clinical relevance of maintaining the functional integrity of the stratum corneum in both healthy and disease-affected skin. J Clin Aesthet Dermatol. 2011;4:22-42.
25. Torok HM. Rosacea skin care. Cutis. 2000;66(suppl 4):14-16.
26. Del Rosso JQ, Baum EW. Comprehensive medical management of rosacea: an interim study report and literature review. J Clin Aesthet Dermatol. 2008;1:20-25.
27. Thibotout D, Thieroff-Ekerdt R, Graupe K. Efficacy and safety of azelaic acid (15%) gel as a new treatment for papulopustular rosacea: results from two vehicle-controlled randomized phase III studies. J Am Acad Dermatol. 2003;48:836-845.
28. Elewski BE, Fleischer AB Jr, Pariser DM. A comparison of 15% azelaic acid gel and 0.75% metronidazole gel in the topical treatment of papulopustular rosacea. Arch Dermatol. 2003;139:1444-1450.
29. Draelos ZD. Treating beyond the histology of rosacea. Cutis. 2004;74(suppl 3):28-31.
30. Subramanyan K. Role of mild cleansing in the management of patient skin. Dermatol Ther. 2004;17(suppl 1):26-34.
31. Levin J, Miller R. A guide to the ingredients and potential benefits of over-the-counter cleansers and moisturizers for rosacea patients. J Clin Aesthet Dermatol. 2011;4:31-49.
32. Pelle MT, Crawford GH, James WD. Rosacea: II. therapy. J Am Acad Dermatol. 2004;51:499-512; quiz 513-514.
33. Del Rosso JQ. Medical treatment of rosacea with emphasis on topical therapies. Expert Opin Pharmacother. 2004;5:5-13.
34. Schlesinger TE, Powell CR. Efficacy and tolerability of low molecular weight hyaluronic acid salt 0.2% cream in rosacea. J Drugs Dermatol. 2013;12:664-667.
35. Bamford JT. Rosacea: current thoughts on origin. Semin Cutan Med Surg. 2001;20:199-206.
36. Hansen C, Leitenberger JJ, Jacobe HT, et al. Photoimmunology. In: Gaspari AA, Tyring SK, eds. Clinical and Basic Immunodermatology. London, England: Springer-Verlag; 2008:147-155.
37. Chung J, Cho S, Kang S. Why does the skin age? intrinsic aging, photoaging, and their pathophysiology. In: Rigel DS, Weiss RA, Lim HW, et al, eds. Photoaging (Basic and Clinical Dermatology). New York, NY: Marcel Dekker; 2004:1-13.
38. Helfrich YR, Varani J, Fisher GJ, et al. Mast cell and neuropeptide expression are increased in erythematotelangiectatic rosacea in comparison to telangiectatic photoaging. Paper presented at: Society of Investigative Dermatology Annual Meeting; May 9, 2012; Raleigh, NC. P093.
39. Oztas MO, Balk M, Ogüs E, et al. The role of free radicals in the aetiopathogenesis of rosacea. Clin Exp Dermatol. 2003;28:188-192.